Pavlos Msaouel1, Richard J Gralla2, Randy A Jones3, Patricia J Hollen3. 1. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 2. Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, New York, USA. 3. University of Virginia, Charlottesville, Virginia, USA.
Abstract
OBJECTIVE: Evidence-based quality of life (QL) questionnaires require the identification of issues of importance to patients. The primary aim of this study was to inform providers on patient-expressed issues while enhancing the content validity of instruments assessing QL and patient-reported outcomes (PROs) in prostate cancer. The study provided additional psychometric properties for the new PRO and QL instrument, the Prostate Cancer Symptom Scale (PCSS). METHODS: An anonymous web-based survey of 2128 patients with prostate cancer was conducted with patients rating 18 QL items on a five-point scale. RESULTS: Most respondents (74%) were aged 55-74 years, had early stage disease at diagnosis (81%) and were diagnosed within 2 years of the survey (81%). The top five-rated issues were: overall QL, ability to perform normal activities, maintaining independence, ability to sleep and not being a burden. These items were ranked as either 'very important' or 'important' by at least 88% of patients. None of the most highly ranked issues were symptoms. Instead, the highest ranked items were global issues reflecting the impact of symptoms on patients. In addition to the enhanced content validity findings, good reliability results and initial support for construct validity are reported for the PCSS. CONCLUSIONS: This is the largest survey providing patient-expressed background for content validity for QL and PRO measures. The findings of this study should aid development of newer practical questionnaires, such as the PCSS, which can be adapted to electronic platforms enhancing rapid and accurate PRO and QL evaluation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: Evidence-based quality of life (QL) questionnaires require the identification of issues of importance to patients. The primary aim of this study was to inform providers on patient-expressed issues while enhancing the content validity of instruments assessing QL and patient-reported outcomes (PROs) in prostate cancer. The study provided additional psychometric properties for the new PRO and QL instrument, the Prostate Cancer Symptom Scale (PCSS). METHODS: An anonymous web-based survey of 2128 patients with prostate cancer was conducted with patients rating 18 QL items on a five-point scale. RESULTS: Most respondents (74%) were aged 55-74 years, had early stage disease at diagnosis (81%) and were diagnosed within 2 years of the survey (81%). The top five-rated issues were: overall QL, ability to perform normal activities, maintaining independence, ability to sleep and not being a burden. These items were ranked as either 'very important' or 'important' by at least 88% of patients. None of the most highly ranked issues were symptoms. Instead, the highest ranked items were global issues reflecting the impact of symptoms on patients. In addition to the enhanced content validity findings, good reliability results and initial support for construct validity are reported for the PCSS. CONCLUSIONS: This is the largest survey providing patient-expressed background for content validity for QL and PRO measures. The findings of this study should aid development of newer practical questionnaires, such as the PCSS, which can be adapted to electronic platforms enhancing rapid and accurate PRO and QL evaluation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
PCSS; Quality of life evaluation; patient reported outcomes; prostate cancer; psychometric properties
Authors: Patricia J Hollen; Richard J Gralla; John A Stewart; Jacinta M Meharchand; Rafal Wierzbicki; Natasha Leighl Journal: Support Care Cancer Date: 2012-06-10 Impact factor: 3.603
Authors: P J Hollen; R J Gralla; M G Kris; C Cox; C P Belani; S M Grunberg; J Crawford; J A Neidhart Journal: Cancer Date: 1994-04-15 Impact factor: 6.860
Authors: George van Andel; Andrew Bottomley; Sophie D Fosså; Fabio Efficace; Corneel Coens; Stephane Guerif; Howard Kynaston; Paolo Gontero; George Thalmann; Atif Akdas; Sven D'Haese; Neil K Aaronson Journal: Eur J Cancer Date: 2008-09-05 Impact factor: 9.162
Authors: Sylvie D Lambert; Lindsay R Duncan; S Nicole Culos-Reed; Laura Hallward; Celestia S Higano; Ekaterina Loban; Anne Katz; Manon De Raad; Janet Ellis; Melissa B Korman; Carly Sears; Cindy Ibberson; Lauren Walker; Eric Belzile; Paramita Saha-Chaudhuri; Helen McTaggart-Cowan; Stuart Peacock Journal: Curr Oncol Date: 2022-02-01 Impact factor: 3.677